DCTH: Delcath Systems Inc Short-Term Debt to Equity

The price action for Delcath Systems, Inc. (DCTH) shown on this chart demonstrates the business development of its targeted liver cancer therapy, where FDA approval has transitioned research into commercial success. The indicator stands at 0.00. Growth is supported by a staff of engineers and physicians motivated by RSU shares and a life-saving mission. Patents for isolation systems and stringent regulatory requirements provide a high level of protection.

Investors must evaluate the financial autonomy of Delcath Systems, Inc. (DCTH) as it deploys commercial sales of its liver therapy. In an environment of organic growth without mergers, reliance on short-term refinancing could create critical liquidity risks. This short-term debt-to-equity ratio measures the proportion of liabilities maturing within one year relative to shareholders' equity. An increase in this metric signals a shortage of long-term resources and potential instability in the business model.